# Clinical Trials Data EGFR - Document 32

# Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01767974

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Locally advanced stage IIIB not suitable for curative therapy or stage IV (metastatic) disease or relapsed NSCLC\n\* ECOG Performance status 0\\~2.\n\* Written Informed Consent\n\* Female or male patients aged 18 years or over, eligible for treatment for NSCLC\n\nExclusion Criteria:\n\n\* Previous exposure to EGFR-TKI\n\* Concomitant use of other anti-cancer drugs with EGFR-TKI\n\* Patients without available Tumor DNA\n\* As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)\n\* Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study\n\* Pregnancy or breast-feeding women (women of child\u00acbearing potential). Women of childbearing potential must practice acceptable methods of birth control to prevent pregnancy.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
"stdAges": [  
"CHILD",  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Locally advanced stage IIIB or IV (metastatic) or Relapsed Non-Small Cell Lung Cancer",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
The clinical trial eligibility criteria you provided does not explicitly list an EGFR gene mutation as an inclusion or exclusion criterion. However, there are certain criteria that could indirectly affect the eligibility of a patient with an EGFR mutation:  
  
1. \*\*Previous exposure to EGFR-TKI\*\*: If the patient has an EGFR mutation and has been previously treated with an EGFR tyrosine kinase inhibitor (EGFR-TKI), they would be excluded from the trial.  
  
2. \*\*Concomitant use of other anti-cancer drugs with EGFR-TKI\*\*: If the patient is currently using an EGFR-TKI along with other anti-cancer drugs, they would be excluded.  
  
In essence, a patient with an EGFR mutation could potentially be eligible for the trial if they meet all inclusion criteria and do not fall under any of the exclusion criteria, especially the ones related to previous or concurrent use of EGFR-TKIs. Nonetheless, the mutation itself does not appear to be a standalone factor for exclusion or inclusion. It is always best for the patient to discuss eligibility with the trial investigator for a clear determination.